Latest Administration News

Lumos Diagnostics has achieved a major milestone by securing 100% Medicare reimbursement recognition for its FebriDx test across all seven US Medicare Administrative Contractors, paving the way for broader adoption in the American healthcare system.

Lifestyle Communities Limited reported a challenging FY25 marked by a significant $135.5 million after-tax write-down following a VCAT ruling, while signaling early signs of recovery and strategic reset for FY26.

Black Bear Minerals has completed the acquisition of the high-grade Shafter Silver Project in Texas, including $150 million in existing infrastructure, positioning itself strategically amid rising silver demand and geopolitical supply shifts.

Little Green Pharma Ltd reported a 9.6% revenue increase to $19.2 million and slashed its net loss by 73% in the half-year ending September 2025, driven by strong growth in European medicinal cannabis markets.

US Masters Residential Property Group has surpassed its 2025 sales target with over US$200 million in property sales and significantly reduced its debt, while maintaining steady distributions to investors.

Saferoads Holdings has divested its Road Safety Rentals business for $10.8 million, repaid debt, and is now focusing on rebuilding its core product sales with new hires and product innovation.

HomeCo Daily Needs REIT has announced a quarterly cash distribution of 2.15 cents per unit for Q3 2025, including a fund payment component under Australian tax law. The REIT confirms its tax structure intentions for the 2026 financial year.

Amplia Therapeutics has secured positive feedback from the US FDA on its Phase 2b/3 trial design for narmafotinib in pancreatic cancer, paving the way for a late 2026 trial start.

IPH Limited reported solid FY25 profit growth driven by Canadian acquisitions and a promising FY26 start despite challenges in Australia and New Zealand. CEO Andrew Blattman announced his retirement for late 2026, marking a pivotal leadership transition.

Eagle Mountain Mining has reapplied for two cancelled exploration permits covering 12% of its Silver Mountain Project, with no expected disruption to near-term activities.

HeraMED has achieved a significant regulatory milestone with the Therapeutic Goods Administration upgrading its HeraBEAT fetal heart rate monitor to Class IIb, making it the only remote home-use device approved in Australia. This positions the company for a potentially lucrative expansion in the Australian maternity care market.

Island Pharmaceuticals has engaged a top Washington DC government affairs firm to accelerate its US biodefence strategy, focusing on its antiviral drug Galidesivir amid promising FDA regulatory signals.